TY - JOUR
T1 - Association between glucocorticoid-induced osteoporosis and myasthenia gravis
T2 - A cross-sectional study
AU - Konno, Shingo
AU - Suzuki, Shigeaki
AU - Masuda, Masayuki
AU - Nagane, Yuriko
AU - Tsuda, Emiko
AU - Murai, Hiroyuki
AU - Imai, Tomihiro
AU - Fujioka, Toshiki
AU - Suzuki, Norihiro
AU - Utsugisawa, Kimiaki
N1 - Publisher Copyright:
© 2015 Konno et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2015/5/12
Y1 - 2015/5/12
N2 - Purpose: To investigate the association between glucocorticoid-induced osteoporosis and myasthenia gravis (MG) using a cross-sectional survey in Japan. Methods: We studied 363 patients with MG (female 68%; mean age, 57 ± 16 years) who were followed at six Japanese centers between April and July 2012. We evaluated the clinical information of MG and fractures, bone markers, and radiological assessment. Quality of life was measured using an MG-specific battery, MG-QOL15. Results: Glucocorticoids were administered in 283 (78%) of 363 MG patients. Eighteen (6%) of 283 MG patients treated with prednisolone had a history of osteoporotic fractures. The duration of glucocorticoid therapy, but not the dose of prednisolone, was associated with the osteoporotic fractures in MG patients. Bone mineral density was significantly decreased in the MG patients with fractures. The multivariate analyses showed that the total quantitative MG score was the only independent factor associated with osteoporotic fractures (OR = 1.30, 95% CI 1.02-1.67, p = 0.03). MG patients who had experienced fractures reported more severe difficulties in activities of daily living. Conclusion: Glucocorticoid-induced osteoporosis aggravates quality of life in patients with MG.
AB - Purpose: To investigate the association between glucocorticoid-induced osteoporosis and myasthenia gravis (MG) using a cross-sectional survey in Japan. Methods: We studied 363 patients with MG (female 68%; mean age, 57 ± 16 years) who were followed at six Japanese centers between April and July 2012. We evaluated the clinical information of MG and fractures, bone markers, and radiological assessment. Quality of life was measured using an MG-specific battery, MG-QOL15. Results: Glucocorticoids were administered in 283 (78%) of 363 MG patients. Eighteen (6%) of 283 MG patients treated with prednisolone had a history of osteoporotic fractures. The duration of glucocorticoid therapy, but not the dose of prednisolone, was associated with the osteoporotic fractures in MG patients. Bone mineral density was significantly decreased in the MG patients with fractures. The multivariate analyses showed that the total quantitative MG score was the only independent factor associated with osteoporotic fractures (OR = 1.30, 95% CI 1.02-1.67, p = 0.03). MG patients who had experienced fractures reported more severe difficulties in activities of daily living. Conclusion: Glucocorticoid-induced osteoporosis aggravates quality of life in patients with MG.
UR - http://www.scopus.com/inward/record.url?scp=84930674548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930674548&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0126579
DO - 10.1371/journal.pone.0126579
M3 - Article
AN - SCOPUS:84930674548
SN - 1932-6203
VL - 10
JO - PLoS One
JF - PLoS One
IS - 5
M1 - e0126579
ER -